OPXA is currently focused on secondary progressive MS (SPMS) as its first priority, which represents a change from the prior (longer, and more expensive development path) relapse-remitting MS (RRMS). This is a logical move as RRMS is more difficult to measure because it relapses. The SPMS market is 25 - 50% of the overall MS market. My DD indicates the total addressable north american market (the only region where OPXA has established logistics for T-cell extraction) for SPMS is US$ 3b. Of this 3b, because of the low degree of currently available therapies, (only one qualified to-date), my assumption for penetration (after commercialization, which is at a minimum, still years away) is:
* first full fiscal year of commercialization 25% of addressable market or $750m,
* second year $937m (assuming 25% CAGR).

but of course there are. why do you think it didn't break below 1.00?

I've got money stuck in this along with the rest of you. I think we can expect a R/S here before any material changes to the shell.

how can you not love this stock?

What's a good broker to be used for trading EIGH on the greys? Has anyone actually requested and received certs for their EIGH shares? Anyone tried exchanging them for preferred shares with the Co?

Tic toc.. boom

Looks like a good call $heff. I'm no longer flipping any OPXA and holding for anticipated news of a nascent commercial licensing/partnership deal.

OPXA CEO announced as keynote speaker for Cell Therapy Conference in China

http://www.businesswire.com/news/home/20110222005677/en/Opexa-CEO-Invited-Keynote-Speaker-Cell-Therapy

OPXA CEO announced as keynote speaker for Cell Therapy Conference in China

http://www.businesswire.com/news/home/20110222005677/en/Opexa-CEO-Invited-Keynote-Speaker-Cell-Therapy

Good golly, is that $48 per share?

Dec we ran 700% on millions of volume over a few days. Hard to say where this new report will take us- seems a little hard to comprehend to me. In any case, holding and watching with saucer-eyes.

Thanks for the welcome Pro. Regarding OPXA, Neil Warma's powerpoint next week should be a good one, IMO.

interesting thanks pro. i bought at 1.95 too.

How are you playing OPXA, Pro?

OPXA to present at the 13th BIO CEO and Investor Conference Feb 14 @ 4:00p EST

http://fatcatwebproductions.com/the_paper/1829-opexa-present-13th-annual-bio-ceo-investor-conference-february-14

OPXA: Large entries have been tough since the FDA news, suspect there will be plenty of demand for the share/warrant units.

I'll be a buyer of these new shares.

KATX Nice movement here today

Doubled my CCME position this morning

Game, set, match CCME! Best rebuttal I've seen in a long time!

Today CCME seems to found at least a near term foothold in the 16.40 area, doesn't look like a conviction one direction or another to me today. I stayed in.

it was 16 even

I covered mine and went long again here.

Always!

:) Thanks. Nice to meet you sir.

Lessee, I just exited my MMM calls yesterday that I bought on the opening selloff after earnings (20% gainer), I have some APWR Jan 2013 $2.50 strike calls that I hold around $3.30 cost basis, (wish I had bought more) and I have these NFLX puts that I'm either going to be immensely heroic with or I'm gonna lose 8% of my portfolio on. :)

guess i'll have to add that one to my list!

I see my predicament is listed in your new years resolutions there.. don't short the runners

Bought the hell out of NFLX puts this morning.. someone put the brakes on this thing already! lol

Anyone else buying the hell out of NFLX puts today? Guess I'm an idiot.

Added YONG today at 7.36

Looking more and more like bigger buyers are averaging in here. We're being walked down on low volume this morning. I think the big move in OPXA's Q1 is yet to occur.

Should be an exciting year ma'am

OPXA nearing 50/200 SMA bull cross.

OPXA nearing 50/200 SMA bull cross.

Hey there Kei. I'm hopeful getting a green light for P3 trial (and certain plans 'firmed') is the milestone needed to cement a commercial partnership with progressive tranches of funding through P3, to solve the cash problem. Regarding the funding of ongoing (non-P3) operations, it would seem imprudent to me if OPXA hadn't sold some shares into the strength we've seen since the FDA press release.

Smart girl..

No, I don't live in Texas and I don't have the print version. Looks like a good article. There's a reason why I didn't trade the last runup, as I think we're going to see a busy news year in 2011 and I don't claim the ability to predict how and when we will move. I think Neil Warma will need to announce a big commercial partnership for Tovaxin to fund P3.

Is it my imagination, or is the right side of the chasm higher than the left.. and a rainbow??!?

Someone is PM'ing me asking for clarification on my comments regarding EIGH. I have stated that the move to .04 was welcome, that I'm looking forward to retaking some old ground here, starting with .10, and that I wouldn't be so sure that a change in management is mutually exclusive with changes to the ticker/share structure of EIGH. I just thought I'd summarize my thinking on EIGH in the event there are any other Texans out there with more breathing room than they'd like to admit under their ten-gallon hat.